Start the conversation
If you're of a certain age, you've probably heard a financial planner say that you should have some money in fixed income – and the closer to retirement you get, the more you're supposed to own.
Now, I'm not going to wade into the lively debate about investing in bonds. Tens of millions of investors hold them, and there are probably just as many opinions.
But it does bring us back around to the existential question of 21st century investing: How do you collect any meaningful bond yields in a zero-interest rate market?
That's particularly pressing for investors over age 50 – or, really, anyone building a retirement fund for themselves.
Now, I've always believed that the road to a happy, prosperous retirement is paved with tech – even more so in an era of low to no interest rates.
And there's an entire bond market I know whose management's taken that very idea to heart. The leadership team is bringing that notoriously low-tech investment into the 21st century and, even now, reaping remarkable gains for their efforts.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.